3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
7
Ovarian Neoplasms
5
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Metastatic Castration Resistant Prostate Cancer
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostate Cancer Metastatic
1
Primary Myelofibrosis
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Leukemia
1
Leiomyosarcoma
1
Glioblastoma
1
Interventions
pembrolizumab
6
sargramostim
5
Psychiatric Rehabilitation
5
Early Intervention, Educational
5
Magnetic Resonance Spectroscopy
4
Gemcitabine
4
Cyclophosphamide
4
palbociclib
3
Trastuzumab
3
Therapeutics
3
Standard of Care
3
Radiotherapy
3
Oxaliplatin
3
Methods
3
Irinotecan
3
Interferon-alpha
3
Fluorouracil
3
Fluorodeoxyglucose F18
3
Erlotinib Hydrochloride
3
Docetaxel
3
Bortezomib
3
temsirolimus
2
motexafin gadolinium
2
entinostat
2
cemiplimab
2
cediranib
2
Specimen Handling
2
Radiosurgery
2
Practice Guidelines as Topic
2
Paclitaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
rucaparib
×
Genitourinary
×
Clear all
NCT04171700
2023-10-02
LODESTAR
pharmaand GmbH
Phase 2
Terminated
83 enrolled
16 charts